Male and/or female patients aged ≥18 years

Physician-diagnosed asthma for ≥6 months prior to visit 1

Use of low- or medium-dose ICS/LABA^# for ≥3 months prior to visit 1

Worsening of asthma symptoms requiring overuse^¶ of reliever medication at least once within 30 days prior to visit 1

Patient-reported history of one or more severe asthma exacerbations requiring treatment with systemic corticosteroids during the 12 months prior to visit 1, except in the previous 30 days

Ability to perform F_ENO and spirometry assessments at home and complete an asthma symptom diary on a regular basis

Patients with any significant disease or disorder or evidence of drug/substance abuse that would pose a risk to patient safety, interfere with study conduct or impact study results

Any asthma worsening requiring a change in treatment other than the prescribed reliever medication within 30 days prior to visit 1

Medical history of life-threatening asthma, including intubation and admission to an intensive care unit

Medical conditions (except allergic rhinitis) or medications (except ICS) that may influence F_ENO

Concurrent respiratory disease (e.g. cystic fibrosis, idiopathic pulmonary fibrosis or pulmonary arterial hypertension)

Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to visit 1 or during screening/run-in period

A severe exacerbation (resulting in ≥3 days of oral corticosteroids (or one depot intramuscular injection of glucocorticosteroid), an urgent care or emergency room visit resulting in treatment with systemic corticosteroids or an inpatient hospitalisation due to asthma) within 30 days prior to screening

Any disease, other than asthma, or procedure that may necessitate the use of oral/systemic corticosteroids during the treatment period

Current tobacco smoking or a history of smoking for ≥10 pack-years